Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Mupirocin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Mupirocin SCHEMBL14616863 | 0.99 | IARS1 (1.00) | IARS1HTR2A | |
| Mupirocin SCHEMBL18995884 | 0.99 | IARS1 (1.00) | IARS1HTR2A | |
| Mupirocin SCHEMBL19183296 | 0.99 | IARS1 (1.00) | IARS1HTR2A | |
| Mupirocin SCHEMBL15387505 | 0.99 | IARS1 (1.00) | IARS1HTR2A | |
| Mupirocin SCHEMBL1027616 | 0.99 | IARS1 (1.00) | IARS1HTR2A | |
| Mupirocin SCHEMBL15387504 | 0.99 | IARS1 (1.00) | IARS1HTR2A | |
| Mupirocin SCHEMBL2223711 | 0.99 | IARS1 (1.00) | IARS1HTR2A | |
| Mupirocin SCHEMBL3291 | 0.99 | IARS1 (1.00) | IARS1HTR2A | |
| Mupirocin SCHEMBL18998277 | 0.99 | IARS1 (1.00) | IARS1HTR2A | |
| Mupirocin SCHEMBL15307512 | 0.99 | IARS1 (1.00) | IARS1HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7737177-B2 | Processes for preparing crystalline and amorphous mupirocin calcium | TEVA Gyógyszergyár Zártkörüen Müködö Részvénytárasaság (HU) | 2010-06-15 | — | — | US | disclosed |
| US-20080249322-A1 | Processes for preparing crystalline and amorphous mupirocin calcium | GYURICZA LORANT | 2008-10-09 | — | — | US | disclosed |
| EP-1455769-A4 | PROCESSES FOR PREPARING CRYSTALLINE AND AMORPHOUS MUPIROCIN CALCIUM | BIOGAL GYOGYSZERGYAR (HU) | 2004-09-22 | — | — | EP | disclosed |
| EP-1455769-A2 | PROCESSES FOR PREPARING CRYSTALLINE AND AMORPHOUS MUPIROCIN CALCIUM | BIOGAL GYOGYSZERGYAR RT. (HU) | 2004-09-15 | — | — | EP | disclosed |
| US-20040024052-A1 | Processes for preparing crystalline and amorphous mupirocin calcium | TEVA GYOGYSZERGYAR ZARTKORUEN MUKODO RESZVENYTARSASAG (HU) | 2004-02-05 | — | — | US | disclosed |
| WO-2003065975-A2 | PROCESSES FOR PREPARING CRYSTALLINE AND AMORPHOUS MUPIROCIN CALCIUM | BIOGAL GYOGYSZERGYAR RT (HU) | 2003-08-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080249322-A1 | Processes for preparing crystalline and amorphous mupirocin calcium | PMM2, CA2, ACP3 | IARS1 3298/4885HTR2A 4722/4885 |
| US-20040024052-A1 | Processes for preparing crystalline and amorphous mupirocin calcium | PMM2, CA2, UROD | IARS1 3008/4885HTR2A 4502/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.